Valneva's Half-Year 2025 Financial Report: Growth and Strategic Moves

Valneva SE announced its financial results for the first half of 2025, revealing total revenues of €97.6 million, a 37.8% increase from the previous year. Product sales rose to €91.0 million, despite the net loss of €20.8 million driven by the absence of a one-time gain from the previous year. Operating cash burn significantly decreased to €10.9 million, showcasing improved financial management.

The company maintained cash and cash equivalents of €161.3 million as of June 30, 2025, bolstered by €20.1 million from market transactions with U.S. investors. Valneva's financial outlook for 2025 remains positive, with expected product sales growth that could lead to positive cash flow.

Recent strategic agreements include a supply contract with the U.S. Department of Defense and an exclusive arrangement with CSL Seqirus for vaccine distribution in Germany. Meanwhile, regulatory developments have cleared the way for wider use of its chikungunya vaccine, IXCHIQ®, following initial restrictions.